Seres Therapeutics Inc (MCRB) Stock Price, Quote & News

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline pr...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 945 9626

Website: www.serestherapeutics.com

Address:

101 Cambridgepark Drive, Cambridge, United States

EC100 Jul. 17 at 9:28 PM

$MCRB still expecting news this or next week about the payment… very bullish on this one

0 · Reply

BioCrazy1 Jul. 17 at 7:38 PM

$MCRB I just don't see the downside here. The shorting is pure jet fuel on this tiny ass float.

0 · Reply

BioCrazy1 Jul. 17 at 7:01 PM

$MCRB Wow!

0 · Reply

michaelpatton_ Jul. 17 at 6:42 PM

$MCRB

0 · Reply

BioCrazy1 Jul. 17 at 6:22 PM

$MCRB Shwab wants me to lend my shares to shorts. I'm not going to do it! What the hell do shorts know? Shares are hard to borrow right now.

1 · Reply

mktfixer Jul. 17 at 3:44 PM

$MCRB Barclays Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $32 Let's GO !!!

2 · Reply

Electhim Jul. 17 at 3:32 PM

$MCRB looks like the low is in. Time to climb

0 · Reply

IBCandBIOTECH Jul. 17 at 3:28 PM

$MCRB Suspect we hang out around $14 today. Would love to get back in the 15s....

0 · Reply

Electhim Jul. 17 at 3:11 PM

$MCRB we should be green today.

0 · Reply

Electhim Jul. 17 at 3:09 PM

$MCRB mm clown 🤡 not attracting sellers or buyers stupid spread again

0 · Reply

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 7, 2025, 2:18 PM EDT - 2 months ago

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 29, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Apr 23, 2025, 7:00 AM EDT - 3 months ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Mar 13, 2025, 11:04 AM EDT - 4 months ago

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 7:00 AM EST - 4 months ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Mar 3, 2025, 7:00 AM EST - 4 months ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Jan 16, 2025, 7:00 AM EST - 6 months ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 9, 2025, 7:00 AM EST - 6 months ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Dec 16, 2024, 7:00 AM EST - 7 months ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Nov 22, 2024, 7:00 AM EST - 8 months ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 13, 2024, 10:28 AM EST - 8 months ago

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:00 AM EST - 9 months ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Sep 30, 2024, 5:15 PM EDT - 10 months ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 27, 2024, 3:26 PM EDT - 10 months ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 26, 2024, 4:01 PM EDT - 10 months ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 23, 2024, 12:14 AM EDT - 10 months ago

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 13, 2024, 7:00 AM EDT - 10 months ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 12, 2024, 7:00 AM EDT - 11 months ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Aug 13, 2024, 3:35 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Jun 7, 2024, 4:00 PM EDT - 1 year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 6:30 AM EDT - 1 year ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

May 11, 2024, 5:34 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 9:30 AM EDT - 1 year ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX RAPT RVNC

Mar 5, 2024, 3:33 PM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 28, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Jan 9, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Jan 4, 2024, 4:00 PM EST - 1 year ago

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 7:46 PM EST - 1 year ago

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

Nov 28, 2023, 9:18 AM EST - 1 year ago

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

Nov 4, 2023, 11:52 AM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

Oct 30, 2023, 5:30 PM EDT - 1 year ago

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST

Oct 12, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Highlight VOWST™ Data at IDWeek

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

DNLI FHTX MRNA SANA

Sep 7, 2023, 10:00 AM EDT - 2 years ago

Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 1, 2023, 2:03 PM EDT - 2 years ago

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy

Aug 8, 2023, 3:03 PM EDT - 2 years ago

Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Call Transcript

EC100 Jul. 17 at 9:28 PM

$MCRB still expecting news this or next week about the payment… very bullish on this one

0 · Reply

BioCrazy1 Jul. 17 at 7:38 PM

$MCRB I just don't see the downside here. The shorting is pure jet fuel on this tiny ass float.

0 · Reply

BioCrazy1 Jul. 17 at 7:01 PM

$MCRB Wow!

0 · Reply

michaelpatton_ Jul. 17 at 6:42 PM

$MCRB

0 · Reply

BioCrazy1 Jul. 17 at 6:22 PM

$MCRB Shwab wants me to lend my shares to shorts. I'm not going to do it! What the hell do shorts know? Shares are hard to borrow right now.

1 · Reply

mktfixer Jul. 17 at 3:44 PM

$MCRB Barclays Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $32 Let's GO !!!

2 · Reply

Electhim Jul. 17 at 3:32 PM

$MCRB looks like the low is in. Time to climb

0 · Reply

IBCandBIOTECH Jul. 17 at 3:28 PM

$MCRB Suspect we hang out around $14 today. Would love to get back in the 15s....

0 · Reply

Electhim Jul. 17 at 3:11 PM

$MCRB we should be green today.

0 · Reply

Electhim Jul. 17 at 3:09 PM

$MCRB mm clown 🤡 not attracting sellers or buyers stupid spread again

0 · Reply

investhedge Jul. 17 at 3:00 PM

$MCRB recklessly and nonstop being shorted ,

0 · Reply

Electhim Jul. 17 at 2:14 PM

$MCRB on a few thousand shares mm drops it to $13.19 $ 16 was high on Monday

0 · Reply

Tritsortreat2020 Jul. 17 at 1:56 PM

$MCRB look at the swings 🥹

0 · Reply

Whitenoise27 Jul. 17 at 1:02 PM

$MCRB move, motherfucker

0 · Reply

Bulltrader988 Jul. 17 at 2:00 AM

$MCRB 🤔🤔 Eric, we need an official statement about the payment in july... Wondering... 👃👀

1 · Reply

Tritsortreat2020 Jul. 16 at 10:49 PM

$MCRB I’ll say it again, all gains on this stock will be made in 1-3 days. Youre either in, or youre out

2 · Reply

RB818 Jul. 16 at 9:44 PM

$MCRB Thought for sure this morning would have a press release about Nestle payment and whatever else. Not the case. Maybe tomorrow.

0 · Reply

Electhim Jul. 16 at 9:35 PM

$MCRB big move up big correction down. Expecting $13- 13.50 as previously stated

1 · Reply

IBCandBIOTECH Jul. 16 at 8:47 PM

$MCRB Andddddd the pattern is broken. Fun while it lasted.

0 · Reply

coreholder Jul. 16 at 8:10 PM

$MCRB nice CON-solidation Eric. We see you 👁️

0 · Reply

mktfixer Jul. 16 at 8:01 PM

$MCRB heading lower it appears...Expect a dip to $13.50 and then recovery to green tomorrow

0 · Reply

db4 Jul. 16 at 7:07 PM

$MCRB XBI is up 2% ,

0 · Reply

Market Cap	128.10M
Revenue (ttm)	0.00
Net Income (ttm)	140,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	49,500
Avg Vol	114,198
Day's Range	N/A - N/A
Shares Out	8.73M
Stochastic %K	64%
Beta	2.75
Analysts	Sell
Price Target	$13.33